SEC Company Response from Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Aug 4, 2017
Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: Aug. 4, 2017 · CIK: 0001533040 · Accession: 0001193125-17-248863
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-219300
Letter
RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101 | Marlborough, MA 01752
August 4, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Christine Westbrook
Re: RXi Pharmaceuticals Corporation
Registration Statement on Form S-1 (File No. 333-219300)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, RXi Pharmaceuticals Corporation (the “Company”) hereby requests that the effective date of the above-captioned registration statement (the “Registration Statement”) be accelerated so that it becomes effective at 4:00 p.m., Eastern Time, on August 8, 2017, or as soon thereafter as practicable.
Please call Ryan Murr of Gibson, Dunn & Crutcher LLP at (415) 393-8373 as soon as the Registration Statement has been declared effective.
Very truly yours,
RXi PHARMACEUTICALS CORPORATION
Show Raw Text
CORRESP 1 filename1.htm CORRESP RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 | Marlborough, MA 01752 August 4, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Christine Westbrook Re: RXi Pharmaceuticals Corporation Registration Statement on Form S-1 (File No. 333-219300) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, RXi Pharmaceuticals Corporation (the “Company”) hereby requests that the effective date of the above-captioned registration statement (the “Registration Statement”) be accelerated so that it becomes effective at 4:00 p.m., Eastern Time, on August 8, 2017, or as soon thereafter as practicable. Please call Ryan Murr of Gibson, Dunn & Crutcher LLP at (415) 393-8373 as soon as the Registration Statement has been declared effective. Very truly yours, RXi PHARMACEUTICALS CORPORATION By: /s/ Geert Cauwenbergh Name: Geert Cauwenbergh, Dr. Med. Sc. Title: President, Chief Executive Officer and Chief Financial Officer